Browsing by Author Durrant, Simon

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 6 of 6
Issue DateTitleAuthor(s)Citation
2006Allogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF.Bradstock, Kenneth; Butler, Jason; Durrant, Simon; Fuery, Madonna; Grigg, Andrew P.; Hill, Geoffrey R.; Hutchins, Cheryl; Kennedy, Gregor; Morris, Edward S.; Morton, James; Roberts, Andrew; Szer, Jeffrey; Western Clinical School: Westmead Millennium InstituteAllogeneic stem cell transplantation with peripheral blood stem cells mobilized by pegylated G-CSF., Biology Of Blood And Marrow Transplantation, vol.12,(6),2006,pp 603-607
2007Equivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemiaBradstock, Kenneth; Bardy, Peter; Dodds, A. J.; Durrant, Simon; Goh, Kim; Herrmann, Richard; Ma, David; Moore, John; Nivison-Smith, Ian; Schwarer, Anthony; Szer, Jeff; Western Clinical School: Westmead Millennium InstituteEquivalent survival for sibling and unrelated donor allogeneic stem cell transplantation for acute myelogenous leukemia, Biology Of Blood And Marrow Transplantation, vol.13,(5),2007,pp 601-607
2003Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phaseBradstock, Kenneth; Arthur, C.; Branford, Susan; Browett, Peter; Durrant, Simon; Gathmann, I.; Grigg, Andrew P.; Harper, A.; Hughes, T. P.; Joske, D.; Lynch, Kevin; Ma, D.; Rudzki, Zbigniew; Schwarer, Anthony; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium InstituteImatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly disgnosed chronic myeloid leukemia in chronic phase, Leukemia, vol.17,(12),2003,pp 2401-2409
2015An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trialBradstock, Kenneth; Arthur, Christopher; Durrant, Simon; et al, Various; Filshie, Robin; Grigg, Andrew P.; Hughes, Timothy P; Irving, Ian; Lickliter, Jason D; Szer, Jeffrey; Taylor, Kerry; Western Clinical School: Westmead Institute for Medical ResAn imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial, Leukemia & Lymphoma, vol.56, 3, 2015,pp 630-638
2015A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemiaBradstock, Kenneth; Iland, Harry; Kerridge, Ian; McLachlan, Andrew; Boyd, Andrew; Busfield, Samantha; Durrant, Simon; et al, Various; He, Simon Z; Hertzberg, Mark; Kennedy, G; Lewis, Ian D.; Marlton, Paula; Ritchie, David S; Western Clinical School: Westmead Millennium Institute; Central Clinical School: Medicine; School of Public Health: Ctr for Values Ethics & Law in Med; PharmacyA Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia, Leukemia & Lymphoma, vol.56, 5, 2015,pp 1406-1415
2004Real-Time Quantitative Pcr Analysis Can Be Used As A Primary Screen To Identify Patients With Cml Treated With Imatinib Who Have Bcr-Abl Kinase Domain Mutations.Bradstock, Kenneth; Branford, Susan; Browett, Peter; Durrant, Simon; et, al; Grigg, Andrew P.; Parkinson, Ian; Rudzki, Zbigniew; Schwarer, Anthony; Seymour, John F.; Taylor, Kerry; Western Clinical School: Westmead Millennium InstituteReal-Time Quantitative Pcr Analysis Can Be Used As A Primary Screen To Identify Patients With Cml Treated With Imatinib Who Have Bcr-Abl Kinase Domain Mutations., Blood, vol.104,(9),2004,pp 2926-2932